The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
Diabetes Obesity and Metabolism2024Vol. 26(9), pp. 3791–3800
Citations Over TimeTop 10% of 2024 papers
Ming Liu, Weijun Gu, Li Chen, Yanbing Li, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du, Yiming Mu, SoliD trial investigators
Abstract
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
Related Papers
- → Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes(2016)51 cited
- → What role for metformin in type 1 diabetes?(2018)5 cited
- → Metformin for Prevention of Type 2 Diabetes(2004)11 cited
- → Evaluation of the metformin initiation rate in veterans with newly identified type 2 diabetes(2021)
- → Metformin(2022)